Software - Application
Compare Stocks
2 / 10Stock Comparison
SURG vs TMUS
Revenue, margins, valuation, and 5-year total return — side by side.
Telecommunications Services
SURG vs TMUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Software - Application | Telecommunications Services |
| Market Cap | $11M | $210.16B |
| Revenue (TTM) | $50M | $90.53B |
| Net Income (TTM) | $-42M | $10.54B |
| Gross Margin | -38.6% | 54.3% |
| Operating Margin | -78.8% | 20.4% |
| Forward P/E | — | 18.5x |
| Total Debt | $5M | $122.27B |
| Cash & Equiv. | $12M | $5.60B |
SURG vs TMUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SurgePays, Inc. (SURG) | 100 | 3.6 | -96.4% |
| T-Mobile US, Inc. (TMUS) | 100 | 194.1 | +94.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SURG vs TMUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SURG is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.30, Low D/E 30.1%, current ratio 2.95x
- Beta 1.30, current ratio 2.95x
- Lower D/E ratio (30.1% vs 206.5%)
TMUS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 8.5%, EPS growth 0.6%, 3Y rev CAGR 3.5%
- 407.2% 10Y total return vs SURG's -99.1%
- 8.5% revenue growth vs SURG's -55.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.5% revenue growth vs SURG's -55.6% | |
| Quality / Margins | 11.6% margin vs SURG's -83.4% | |
| Stability / Safety | Lower D/E ratio (30.1% vs 206.5%) | |
| Dividends | 1.9% yield; 3-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -21.2% vs SURG's -78.9% | |
| Efficiency (ROA) | 4.9% ROA vs SURG's -242.4%, ROIC 8.1% vs -229.7% |
SURG vs TMUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SURG vs TMUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
TMUS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMUS is the larger business by revenue, generating $90.5B annually — 1797.2x SURG's $50M. TMUS is the more profitable business, keeping 11.6% of every revenue dollar as net income compared to SURG's -83.4%. On growth, SURG holds the edge at +2.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $50M | $90.5B |
| EBITDAEarnings before interest/tax | -$39M | $29.9B |
| Net IncomeAfter-tax profit | -$42M | $10.5B |
| Free Cash FlowCash after capex | -$26M | $10.7B |
| Gross MarginGross profit ÷ Revenue | -38.6% | +54.3% |
| Operating MarginEBIT ÷ Revenue | -78.8% | +20.4% |
| Net MarginNet income ÷ Revenue | -83.4% | +11.6% |
| FCF MarginFCF ÷ Revenue | -50.9% | +11.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.9% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +47.2% | -12.0% |
Valuation Metrics
SURG leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $11M | $210.2B |
| Enterprise ValueMkt cap + debt − cash | $4M | $326.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.23x | 19.98x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 18.45x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.67x |
| EV / EBITDAEnterprise value multiple | — | 10.13x |
| Price / SalesMarket cap ÷ Revenue | 0.18x | 2.38x |
| Price / BookPrice ÷ Book value/share | 0.70x | 3.71x |
| Price / FCFMarket cap ÷ FCF | — | 20.32x |
Profitability & Efficiency
TMUS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TMUS delivers a 17.8% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-10 for SURG. SURG carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMUS's 2.07x. On the Piotroski fundamental quality scale (0–9), TMUS scores 6/9 vs SURG's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -10.1% | +17.8% |
| ROA (TTM)Return on assets | -2.4% | +4.9% |
| ROICReturn on invested capital | -2.3% | +8.1% |
| ROCEReturn on capital employed | -177.3% | +9.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | 0.30x | 2.07x |
| Net DebtTotal debt minus cash | -$7M | $116.7B |
| Cash & Equiv.Liquid assets | $12M | $5.6B |
| Total DebtShort + long-term debt | $5M | $122.3B |
| Interest CoverageEBIT ÷ Interest expense | -40.65x | 5.33x |
Total Returns (Dividends Reinvested)
TMUS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMUS five years ago would be worth $14,546 today (with dividends reinvested), compared to $715 for SURG. Over the past 12 months, TMUS leads with a -21.2% total return vs SURG's -78.9%. The 3-year compound annual growth rate (CAGR) favors TMUS at 12.0% vs SURG's -49.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -67.4% | -2.2% |
| 1-Year ReturnPast 12 months | -78.9% | -21.2% |
| 3-Year ReturnCumulative with dividends | -86.9% | +40.4% |
| 5-Year ReturnCumulative with dividends | -92.8% | +45.5% |
| 10-Year ReturnCumulative with dividends | -99.1% | +407.2% |
| CAGR (3Y)Annualised 3-year return | -49.3% | +12.0% |
Risk & Volatility
TMUS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMUS is the less volatile stock with a -0.28 beta — it tends to amplify market swings less than SURG's 1.30 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMUS currently trades 74.2% from its 52-week high vs SURG's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.30x | -0.28x |
| 52-Week HighHighest price in past year | $3.45 | $261.56 |
| 52-Week LowLowest price in past year | $0.46 | $181.36 |
| % of 52W HighCurrent price vs 52-week peak | +16.2% | +74.2% |
| RSI (14)Momentum oscillator 0–100 | 39.9 | 45.5 |
| Avg Volume (50D)Average daily shares traded | 378K | 5.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
TMUS is the only dividend payer here at 1.88% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $254.08 |
| # AnalystsCovering analysts | — | 54 |
| Dividend YieldAnnual dividend ÷ price | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | 3 |
| Dividend / ShareAnnual DPS | — | $3.64 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.6% | +4.7% |
TMUS leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SURG leads in 1 (Valuation Metrics).
SURG vs TMUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SURG or TMUS a better buy right now?
For growth investors, T-Mobile US, Inc.
(TMUS) is the stronger pick with 8. 5% revenue growth year-over-year, versus -55. 6% for SurgePays, Inc. (SURG). T-Mobile US, Inc. (TMUS) offers the better valuation at 20. 0x trailing P/E (18. 5x forward), making it the more compelling value choice. Analysts rate T-Mobile US, Inc. (TMUS) a "Buy" — based on 54 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SURG or TMUS?
Over the past 5 years, T-Mobile US, Inc.
(TMUS) delivered a total return of +45. 5%, compared to -92. 8% for SurgePays, Inc. (SURG). Over 10 years, the gap is even starker: TMUS returned +407. 2% versus SURG's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SURG or TMUS?
By beta (market sensitivity over 5 years), T-Mobile US, Inc.
(TMUS) is the lower-risk stock at -0. 28β versus SurgePays, Inc. 's 1. 30β — meaning SURG is approximately -565% more volatile than TMUS relative to the S&P 500. On balance sheet safety, SurgePays, Inc. (SURG) carries a lower debt/equity ratio of 30% versus 2% for T-Mobile US, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SURG or TMUS?
By revenue growth (latest reported year), T-Mobile US, Inc.
(TMUS) is pulling ahead at 8. 5% versus -55. 6% for SurgePays, Inc. (SURG). On earnings-per-share growth, the picture is similar: T-Mobile US, Inc. grew EPS 0. 6% year-over-year, compared to -273. 2% for SurgePays, Inc.. Over a 3-year CAGR, SURG leads at 6. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SURG or TMUS?
T-Mobile US, Inc.
(TMUS) is the more profitable company, earning 12. 4% net margin versus -75. 1% for SurgePays, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMUS leads at 21. 2% versus -68. 6% for SURG. At the gross margin level — before operating expenses — TMUS leads at 47. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SURG or TMUS?
In this comparison, TMUS (1.
9% yield) pays a dividend. SURG does not pay a meaningful dividend and should not be held primarily for income.
07Is SURG or TMUS better for a retirement portfolio?
For long-horizon retirement investors, T-Mobile US, Inc.
(TMUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 28), 1. 9% yield, +407. 2% 10Y return). Both have compounded well over 10 years (TMUS: +407. 2%, SURG: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SURG and TMUS?
These companies operate in different sectors (SURG (Technology) and TMUS (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
TMUS pays a dividend while SURG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.